Text Size

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)

This study has been completed.
Sponsor:
Information provided by:
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01272908
First received: January 7, 2011
Last updated: NA
Last verified: January 2011
History: No changes posted
  Purpose

This study will evaluate the safety and effectiveness of MabThera (rituximab) in patients with active rheumatoid arthritis who are receiving methotrexate, and who have a previous or current inadequate response to one prior anti-TNF therapy. All patients will receive MabThera 1000 mg as an intravenous infusion on days 1 and 15. After the initial study phase of 24 weeks, eligible patients may receive one re-treatment with MabThera. The anticipated time on study treatment is 48 weeks.


Condition Intervention Phase
Rheumatoid Arthritis
 Drug: rituximab
 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Rituximab Phase IIIb Open-label, Multi-centre Assessment of Safety and Effectiveness in Patients With RA Following an Inadequate Response to One Prior Anti-TNF Inhibitor (RESET)

Resource links provided by NLM:

Drug Information available for: Rituximab
U.S. FDA Resources

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Overall incidence of Adverse Events for 48 weeks after initial treatment [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Incidence of adverse events after re-treatment with MabThera [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients meeting American College of Rheumatology Criteria (ACR 20/50/70) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients meeting European League Against Rheumatism (EULAR) response rates [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in Disease Activity Score (DAS28) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline in American College of Rheumatology Criteria (ACR) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in Health Assessment Questionnaire (HAQ) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]

Enrollment: 120
Study Completion Date: August 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single arm Drug: rituximab
1000 mg intravenously on Days 1 and 15

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients, 18-80 years of age
  • Moderate to severe active rheumatoid arthritis
  • Inadequate response to a single previous or current treatment with an anti-TNF agent
  • Methotrexate for at least 12 weeks, at a stable dose over the past 4 weeks

Exclusion Criteria:

  • Previous treatment with MabThera
  • Use of an anti-TNF agent within past 8 weeks (4 in the case of etanercept)
  • Concurrent treatment with any Disease Modifying Anti-Rheumatic Drug (DMARD) other than methotrexate
  • Active infection, or history of serious or chronic infection
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01272908

  Hide Study Locations
Locations
Canada, Alberta
Edmonton, Alberta, Canada, T5M 0H4
Edmonton, Alberta, Canada, T6G 2B7
Canada, British Columbia
Kelowna, British Columbia, Canada, V1Y 3G8
Vancouver, British Columbia, Canada, V5Z 3Y1
Victoria, British Columbia, Canada, V8V 3P9
Canada, Manitoba
Winnipeg, Manitoba, Canada, R3A 1M4
Canada, Newfoundland and Labrador
St John's, Newfoundland and Labrador, Canada, A1C 5B8
St John's, Newfoundland and Labrador, Canada, A1A 5E8
Canada, Ontario
Hamilton, Ontario, Canada, L8S 4J9
Hamilton, Ontario, Canada, L8N 1Y2
Mississauga, Ontario, Canada, L5M 2V8
Nepean, Ontario, Canada, K2G 6E2
Ottawa, Ontario, Canada, K1S 1C2
Ottawa, Ontario, Canada, K1H 8L6
Thunder Bay, Ontario, Canada, P7B 5G3
Toronto, Ontario, Canada, M4K 1N2
Toronto, Ontario, Canada, M5G 1X5
Toronto, Ontario, Canada, M5T 2S8
Windsor, Ontario, Canada, N8X 5A6
Canada, Quebec
Laval, Quebec, Canada, H7G 2E6
Montreal, Quebec, Canada, H3T 1E2
Montreal, Quebec, Canada, H1T 2M4
Montreal, Quebec, Canada, H2L 1S6
Montreal, Quebec, Canada, H2L 4M1
Quebec City, Quebec, Canada, G1V 3M7
Sainte-foy, Quebec, Canada, G1W 4R4
Sherbrooke, Quebec, Canada, J1H 5N4
St-eustache, Quebec, Canada, J7P 4J2
Trois-rivieres, Quebec, Canada, G8Z 1Y2
Sweden
Boras, Sweden, 50182
Falun, Sweden, 79182
Goeteborg, Sweden, 41345
Jonkoping, Sweden, 551 85
Kalmar, Sweden, 39185
Karlskrona, Sweden, 37185
Lulea, Sweden, 97180
Malmoe, Sweden, 20502
Oskarstroem, Sweden, 31392
Skoevde, Sweden, 54185
Stockholm, Sweden, 18288
Sundsvall, Sweden, 85186
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Chair: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Disclosures Group, Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01272908     History of Changes
Other Study ID Numbers: ML20381
Study First Received: January 7, 2011
Last Updated: January 7, 2011
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
 Rituximab
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Antineoplastic Agents

ClinicalTrials.gov processed this record on May 16, 2013